Mecocci P, Parnetti L, Donato R, Santucci C, Santucci A, Cadini D, Foà E, Cecchetti R, Senin U
Institute of Gerontology and Geriatrics, University of Perugia, Italy.
Brain Behav Immun. 1992 Sep;6(3):286-92. doi: 10.1016/0889-1591(92)90049-t.
Autoantibodies against glial fibrillary acidic protein (GFAP) were investigated by ELISA test in sera of patients suffering from senile dementias and in healthy aging people. One hundred eight subjects divided into control, vascular dementia (VD), presenile Alzheimer's disease (AD), and senile Alzheimer's disease (SDAT) groups were included in the study. VD patients showed the highest antibody titers when compared to controls, whereas AD had the lowest titers when compared to the other groups. These results do not support the utility of anti-GFAP antibodies as useful markers of Alzheimer's disease, suggesting that their presence is a secondary phenomenon to blood-brain barrier disruption.
通过酶联免疫吸附测定（ELISA）试验，对患有老年痴呆症的患者血清以及健康老年人血清中的抗胶质纤维酸性蛋白（GFAP）自身抗体进行了研究。该研究纳入了108名受试者，分为对照组、血管性痴呆（VD）组、早老性阿尔茨海默病（AD）组和老年性阿尔茨海默病（SDAT）组。与对照组相比，VD患者的抗体滴度最高，而与其他组相比，AD患者的抗体滴度最低。这些结果不支持抗GFAP抗体作为阿尔茨海默病有用标志物的效用，表明它们的存在是血脑屏障破坏的继发现象。
